Skip to main content
Top
Published in: International Orthopaedics 3/2017

01-03-2017 | Original Paper

The dual mobility cup in muscular skeletal oncology: rationale and indications

Published in: International Orthopaedics | Issue 3/2017

Login to get access

Abstract

Purpose

Because of the improvement of medical therapy and the corresponding increase in life expectancy, orthopaedic surgeons are obliged to perform more wide resections rather than intramedullary stabilization nailing for patients affected by tumours of the hip compared to the past. Wide resection often causes joint instability, so prosthetic reconstruction presents a higher risk of dislocation than in primary osteoarthritis cases. The aim of the present paper is to classify the indications for the dual mobility cup (DMC) hip prosthesis based on the anatomic structures involved in the disease and to analyse the rationale to reduce the risk of dislocation.

Methods

Indications were analyzed and classified based on all the cases in which the DMC prosthesis was used for reconstruction after hip resection in an oncological research hospital.

Results

Four classes of indications were identified; for classes I and IV the indication for DMC prosthesis can be considered strong; for classes II and III the indications must be evaluated considering the specific case, based on life expectancy, performance status, presence of osteoarthritis, and availability of adjuvant local therapies. When the DMC prosthesis is indicated, the cup should always be cemented, either alone or with augmentation techniques, to decrease the risk of mobilization due to local disease progression.

Conclusions

DMC can be a valid alternative in reconstruction of the hip after tumor removal; nevertheless, prospective, randomized studies are necessary to verify the real dislocation rate based on the entity of resection.
Literature
1.
go back to reference Campanacci M (1999) Bone and soft tissue tumors. Springer-Verlag Wien, New YorkCrossRef Campanacci M (1999) Bone and soft tissue tumors. Springer-Verlag Wien, New YorkCrossRef
2.
go back to reference Zoccali C, Soriani A, Rossi B, Salducca N, Biagini R (2016) The Carbofix™ “Piccolo Proximal femur nail”: a new perspective for treating proximal femur lesion. A technique report. J Orthop 13(4):343–6CrossRefPubMed Zoccali C, Soriani A, Rossi B, Salducca N, Biagini R (2016) The Carbofix™ “Piccolo Proximal femur nail”: a new perspective for treating proximal femur lesion. A technique report. J Orthop 13(4):343–6CrossRefPubMed
3.
go back to reference Gao H, Liu Z, Wang B, Guo A (2016) Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis. Chin J Cancer Res 28(2):209–14CrossRefPubMedPubMedCentral Gao H, Liu Z, Wang B, Guo A (2016) Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis. Chin J Cancer Res 28(2):209–14CrossRefPubMedPubMedCentral
4.
go back to reference Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D’Amico R (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. (6):CD006242 Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D’Amico R (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. (6):CD006242
5.
go back to reference Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 7:CD008941 Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 7:CD008941
6.
go back to reference Jacofsky DJ, Haidukewych GJ, Zhang H, Sim FH (2004) Complications and results of arthroplasty for salvage of failed treatment of malignant pathologic fractures of the hip. Clin Orthop 427:52–6CrossRef Jacofsky DJ, Haidukewych GJ, Zhang H, Sim FH (2004) Complications and results of arthroplasty for salvage of failed treatment of malignant pathologic fractures of the hip. Clin Orthop 427:52–6CrossRef
7.
go back to reference Kunisada T, Choong PF (2000) Major reconstruction for periacetabular metastasis: early complications and outcome following surgical treatment in 40 hips. Acta Orthop Scand 71:585–90CrossRefPubMed Kunisada T, Choong PF (2000) Major reconstruction for periacetabular metastasis: early complications and outcome following surgical treatment in 40 hips. Acta Orthop Scand 71:585–90CrossRefPubMed
8.
go back to reference Zehr RJ, Enneking WF, Scarborough MT (1996) Allograft-prosthesis composite versus megaprosthesis in proximal femoral reconstruction. Clin Orthop 322:207–23CrossRef Zehr RJ, Enneking WF, Scarborough MT (1996) Allograft-prosthesis composite versus megaprosthesis in proximal femoral reconstruction. Clin Orthop 322:207–23CrossRef
9.
go back to reference Surace MF, Monestier L, D’Angelo F, Bertagnon A (2016) Factors predisposing to dislocation after primary total hip arthroplasty: a multivariate analysis of risk factors at 7 to 10 years follow-up. Surg Technol Int 30 Surace MF, Monestier L, D’Angelo F, Bertagnon A (2016) Factors predisposing to dislocation after primary total hip arthroplasty: a multivariate analysis of risk factors at 7 to 10 years follow-up. Surg Technol Int 30
11.
go back to reference Hernigou P, Ratte L, Roubineau F, Pariat J, Mirouse G, Guissou I, Allain J, Lachaniette CH (2013) The risk of dislocation after total hip arthroplasty for fractures is decreased with retentive zups. Int Orthop 37(7):1219–23CrossRefPubMedPubMedCentral Hernigou P, Ratte L, Roubineau F, Pariat J, Mirouse G, Guissou I, Allain J, Lachaniette CH (2013) The risk of dislocation after total hip arthroplasty for fractures is decreased with retentive zups. Int Orthop 37(7):1219–23CrossRefPubMedPubMedCentral
12.
go back to reference Gosheger G, Hillmann A, Lindner N, Rödl R, Hoffmann C, Bürger H, Winkelmann W (2001) Soft tissue reconstruction of megaprostheses using a trevira tube. Clin Orthop Relat Res 393:264–71CrossRef Gosheger G, Hillmann A, Lindner N, Rödl R, Hoffmann C, Bürger H, Winkelmann W (2001) Soft tissue reconstruction of megaprostheses using a trevira tube. Clin Orthop Relat Res 393:264–71CrossRef
13.
go back to reference Mountney J, Garbuz DS, Greidanus NV, Masri BA, Duncan CP (2004) Cementing constrained acetabular liners in revision hip replacement: clinical and laboratory observations. Instr Course Lect 53:131–40PubMed Mountney J, Garbuz DS, Greidanus NV, Masri BA, Duncan CP (2004) Cementing constrained acetabular liners in revision hip replacement: clinical and laboratory observations. Instr Course Lect 53:131–40PubMed
14.
go back to reference Noble PC, Durrani SK, Usrey MM, Mathis KB, Bardakos NV (2012) Constrained cups appear incapable of meeting the demands of revision THA. Clin Orthop Relat Res 470(7):1907–16CrossRefPubMed Noble PC, Durrani SK, Usrey MM, Mathis KB, Bardakos NV (2012) Constrained cups appear incapable of meeting the demands of revision THA. Clin Orthop Relat Res 470(7):1907–16CrossRefPubMed
15.
go back to reference Rossi B, Zoccali C, Toma L, Ferraresi V, Biagini R (2016) Surgical site infections in treatment of musculoskeletal tumors: experience from a single oncologic orthopedic institution. J Orthop Oncol 2:1CrossRef Rossi B, Zoccali C, Toma L, Ferraresi V, Biagini R (2016) Surgical site infections in treatment of musculoskeletal tumors: experience from a single oncologic orthopedic institution. J Orthop Oncol 2:1CrossRef
16.
go back to reference Caton JH, Prudhon JL, Ferreira A, Aslanian T, Verdier R (2014) A comparative and retrospective study of three hundred and twenty primary Charnley type hip replacements with a minimum follow up of ten years to assess whether a DMC has a decreased dislocation risk. Int Orthop 38(6):1125–9CrossRefPubMedPubMedCentral Caton JH, Prudhon JL, Ferreira A, Aslanian T, Verdier R (2014) A comparative and retrospective study of three hundred and twenty primary Charnley type hip replacements with a minimum follow up of ten years to assess whether a DMC has a decreased dislocation risk. Int Orthop 38(6):1125–9CrossRefPubMedPubMedCentral
17.
go back to reference Philippeau JM, Durand JM, Carret JP, Leclercq S, Waast D, Gouin F (2010) Dual mobility design use in preventing total hip replacement dislocation following tumor resection. Orthop Traumatol Surg Res 96(1):2–8CrossRefPubMed Philippeau JM, Durand JM, Carret JP, Leclercq S, Waast D, Gouin F (2010) Dual mobility design use in preventing total hip replacement dislocation following tumor resection. Orthop Traumatol Surg Res 96(1):2–8CrossRefPubMed
Metadata
Title
The dual mobility cup in muscular skeletal oncology: rationale and indications
Publication date
01-03-2017
Published in
International Orthopaedics / Issue 3/2017
Print ISSN: 0341-2695
Electronic ISSN: 1432-5195
DOI
https://doi.org/10.1007/s00264-017-3407-4

Other articles of this Issue 3/2017

International Orthopaedics 3/2017 Go to the issue